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Effects of different antihypertensive treatments on morphologic pro-
gression of diabetic nephropathy in uninephrectomized dogs. We previ-
ously reported the renal hemodynamic effects of different antihyperten-
sive regimens in uninephrectomized, alloxan-induced, diabetic (DM)
beagle dogs following one year of treatment. Dogs were prospectively
randomized to one of five groups (N = 26): nondiabetic controls, Group
I; dogs with DM on no antihypertensive drugs, Group II; dogs on a
converting enzyme inhibitor, lisinopril (L), Group III; dogs on
a calcium antagonist, TA3090 (diltiazem-like), Group IV; and dogs on a
combination of each drug, in reduced doses, Group V . The current
paper extends our previous studies by describing the morphologic
changes that occurred within each group of dogs studied. More than 100
glomeruli from the renal cortex of each dog were evaluated for
increases in mesangial volume fraction (V), glomeruloscierosis (GS)
and arteriolar hyalinosis. The interstitium was also evaluated for
associated changes. Increases in V, were attenuated in all treated
groups (0.28 0.04, DM alone versus 0.16 0.05 L; 0.21 0.07,
TA-3090; 0.19 0.06 m2/m2, L + TA 3090; P < 0.05) compared to
untreated DM. An attenuated increase in V, also correlated with a
blunted rise in proteinuria in Groups III (r = 0.79) and V (r = 0.81) but
not Group IV (r = 0.29). Development of focal GS was blunted in all
treated groups; however, global GS was fourfold greater in Group IV
compared to untreated DM. The degree of interstitial fibrosis also
correlated with the degree of global GS. These data support the concept
that both a converting enzyme inhibitor and heart rate lowering calcium
antagonist attenuate morphologic progression of diabetic renal disease.
When used alone, however, the calcium antagonist increases develop-
ment of global GS, an effect that appears to be independent of blood
pressure control.
Diabetic nephropathy is a major cause of end-stage renal
disease in the United States [1, 21. Reduction of both elevated
arterial pressure and albuminuria, which portends this disease
process, attenuates progression of renal dysfunction and re-
duces mortality [3—7]. A maintained reduction in arterial pres-
sure, however, has not been shown to stop progression of
diabetic renal disease [5,8]. Thus, elevation in arterial pressure
is not the only factor that contributes to renal demise from
diabetes.
Numerous studies document that morphologic changes occur
in the kidneys of diabetic patients prior to any clinical findings
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of microalbuminuria or hypertension [9—11]. Specifically, these
studies demonstrate an increase in the matrix component of the
mesangium as an early morphologic manifestation of diabetic
nephropathy. They further illustrate that focal glomeruloscle-
rosis (GS) occurs significantly after the presence of these
mesangial changes. Unfortunately, focal GS is not an early
finding of this disease in humans. Focal GS, however, is the
earliest morphologic change in the most common animal model
studied, the diabetic rat [12—161. This is due to a failure of the
matrix component of the mesangium to continuously expand
beyond that which occurs in the very early stages of the
disease. Diabetic beagle dogs, however, may be a better model
to study this aspect of glomerular disease. These dogs manifest
continuous increases in the matrix component of the mesangial
volume fraction for at least five years after the induction of
diabetes [17—18].
Recent studies in diabetic rats have compared the effects of
various antihypertensive agents on morphologic changes asso-
ciated with disease progression. In general, these studies dem-
onstrate an attenuation in both focal and global GS with most
agents [12—14]. Moreover, these investigations document that
converting enzyme inhibitors have the greatest effect on atten-
uating progression to GS. Unlike other antihypertensive agents,
most studies in either diabetic or hypertensive rats with dihy-
dropyridine calcium antagonists (nifedipine-like) fail to show
any effect on the development of focal GS [14, 19—22]. In
addition, these agents have been associated with an increased
development of global GS [19, 21]. Moreover, there are no
studies in an appropriate animal model that have examined the
effects of heart-rate lowering calcium antagonists or converting
enzyme inhibitors on expansion of the matrix component of the
mesangium. One recent study in diabetic, normotensive rats
evaluated the effects of both therapy with three drugs (diuretic,
hydralazine, reserpine) and converting enzyme inhibition on
mesangial expansion [23]. These investigators found no signif-
icant effect of either therapeutic regimen on the expansion of
mesangial volume. They attributed this lack of effect to poor
glycemic control rather than changes in arterial pressure.
We recently conducted a randomized, prospective study in
unilaterally nephrectomized, alloxan-induced diabetic beagle
dogs that assessed the renal hemodynamic effects of a convert-
ing enzyme inhibitor, lisinopril, or heart-rate-lowering calcium
antagonist, TA 3090 (diltiazem-like), alone and in combination
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following one year of treatment [24, 25]. The specific method-
ology for this renal hemodynamic study has been published
elsewhere [25]. To summarize the salient features of this study:
intraarterial blood pressures were assessed weekly to achieve a
goal mean arterial pressure of < 106 mm Hg. Thereafter, blood
pressures were assessed monthly. Fasting blood glucose values
were evaluated daily. No significant differences were present in
any of the treated groups for either blood pressure control or
fasting blood glucose values over the duration of the study. The
kidneys of all animals, except those on combination therapy,
were micropunctured at one year. There was a significant
increase in both glomerular capillary pressure and volume in the
untreated diabetic group compared to controls. Treatment with
lisinopril reduced both the glomerular capillary pressure and
volume. TA 3090, however, only reduced glomerular volume.
Lastly, the increase in urinary protein excretion, measured by a
spectro-photometric method, was significantly blunted by both
agents. The greatest effect on the rise in proteinuria, however,
was seen in the group that received both lisinopril and TA 3090.
This paper extends our previous results by focusing on
morphologic changes that occurred in the kidney of each dog
following one year of treatment. The principal objective of this
study was to evaluate the changes in mesangial volume fraction
and degree of focal and global GS that developed within each
group of dogs in the presence and absence of arterial pressure
reduction with different classes of antihypertensive drugs. In
addition, we also assessed tubulointerstitial changes, a morpho-
logic parameter that has been suggested to antedate the devel-
opment of mesangial volume expansion in this disease. The
results of these analyses form the basis of this report.
Methods
General
The methods discussed in this section apply solely to evalu-
ations of renal tissues and related procedures. Light micro-
scopic and ultrastructural quantitative analysis were performed
on kidney samples from 26 adult beagle dogs with a mean
weight of 13.0 0.3 kg. All dogs underwent right nephrectomy.
Diabetes mellitus was induced in 20 dogs by intravenous
injection of alloxan, at a dose of 60 mg/kg body weight. The left
renal artery was clamped throughout the infusion period, and
for an additional five minutes to prevent acute tubular necrosis
from alloxan [23]. All dogs were fed a diet which contained
15.4% protein and 0.21% sodium (Hill's Pet Products, Topeka,
Kansas, USA). A control group of uninephrectomized, non-
diabetic dogs, Group 1 (N = 6), were studied at the same time
and in a similar manner to the other groups. All diabetic dogs
received daily subcutaneous insulin therapy throughout the one
year duration of the study. Group II (N = 6) received insulin
alone; Group III (N = 5) received the converting enzyme
inhibitor (CEI), lisinopril, orally; Group IV (N = 5) received
oral administration of the calcium antagonist TA 3090, and
Group V (N = 4) received the combination of a reduced daily
oral dose of both lisinopril and TA3090. Insulin dosage was
adjusted to achieve a goal plasma glucose concentration be-
tween 350 to 450 mg/dl immediately prior to the subsequent
insulin injection. Similarly, the once daily dosages of antihyper-
tensive agents were adjusted to maintain the mean arterial
pressure between 95 and 105 mm Hg.
Histologic specimens and tissue preparation
At the end of one year, the dogs were sacrificed to obtain
samples of the renal cortex. Tissue specimens for light micros-
copy were fixed in 4% buffered formalin mixed with 2%
gluteraldehyde (Trump's fixative) for paraffin processing. A
single two to three m thick section, stained with periodic acid
Sehiff (PAS), was available for light microscopy on each case.
At least 100 glomeruli were present in each section. Several 0.1
mm cubes of renal cortex also fixed in Trump's fixative were
processed by standard electron microscopy techniques with the
addition of in-block staining with 2% uranyl acetate prior to
dehydration. The processed samples were embedded in spur.
One m sections thick were stained with toluidine blue to select
adequate representative tissue samples for ultrastructural ste-
reologic examination. The most centrally located glomerulus in
the block was chosen for thin sections. If three glomeruli could
not be identified in three separate blocks, blocks with more than
one glomerulus were then selected. For each case, two to three
glomeruli were analyzed. Thin sections were collected on
formvar coated, single-slot grids, then stained with 2% uranyl
acetate and lead citrate. Sections were examined and photo-
graphed by a JEOL 2000EX electron microscope (Tokyo,
Japan). Additionally, sections from random kidneys removed at
the inception of the study from each dog were prepared in a
similar manner. These sections were used to determine the
normal range of mesangial volume in these dogs.
Light microscopy
Sections were divided by two perpendicular lines into four
quadrants to facilitate glomerular counting. Based on the loca-
tion and distribution of sclerosis within the glomerular tuft,
three patterns of GS were identified and analyzed. The first
pattern was hilar sclerosis [26]. This was characterized by
expansion of the matrix component of the mesangium into the
vascular pole and the hilar region of the glomerular tuft with
frequent sclerosis and hyalinosis of the periglomerular arteri-
oles (Fig. 1A). The second pattern was focal segmental GS that
involved the peripheral segments of the glomerular tuft result-
ing in collapse and occlusion of the peripheral capillaries, and
adhesion to Bowman's capsule (Fig. 1B). The third pattern was
diffuse GS where the entire glomerular tuft was scierosed (Fig.
2).
Determination of tubulointerstitial changes
The extent of interstitial fibrosis and tubular atrophy was
determined semiquantitatively by examining the PAS stained
sections of renal cortex previously divided by two perpendicu-
lar lines into four quadrants. The degree of tubular changes and
interstitial fibrosis was graded from 0 to 3 + (0 = no changes; 1 +
= changes affecting <20% of the sample; 2+ = changes affect-
ing 20 to 40% of the sample; 3+ = changes affecting > 40% or
the sample). All renal biopsies were analyzed by the same renal
pathologist who was unaware of what treatment each dog
received.
Determination of mesangial volume fraction
Photomontages of the glomerular profiles were made by
taking a series of micrographs using previously described
techniques [27, 28]. The micrographs were printed at a final
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Fig. 1A. Glomerulus from an untreated diabetic dog (group II) showing moderate sclerosis of the glomerular arterioles and the mesangium at the
glomerular hilum. B. Glomerulus from a diabetic dog treated with TA 3090 illustrates the segmental enlargement of the mesangial volume,
obliteration of the peripheral capillary loops and capsular adhesion. (PAS; original magnification x 200).
magnification of x 12,000. Magnification was monitored by
using a carbon calibrated grid (1,134 lines/mm). An average of
60 micrographs was needed to reconstruct a single glomerulus.
The glomerular profile was delineated by the least convex
polygon, whose points connected the epithelial side of the
basement membrane of the most distal capillary loops. A square
lattice grid was then placed over the photomontage for point
counting. The grid was composed of evenly spaced fine and
coarse points at a 1:4 ratio, (Fig. 3). The distance between each
coarse point was 6 mm, and between each fine point was 3 mm.
The following equation was used to calculate the fractional
mesangial volume (V):
EPIEP,, x 4
where EPf is the sum of fine points falling on the mesangial
areas, and EP is the sum of coarse points falling within the
polygon outlining the glomerular profile.
Specific components of the mesangium such as cells and
matrix were not evaluated separately or quantitated to assess
their contribution to the mesangial volume fraction. We as-
sumed, however, that the accepted convention by light micros-
copy, established in normal renal tissue, of  3 cells per
mesangial area was valid [29]. Moreover, the renal biopsy slides
of each dog were reviewed at the end of the one year study. We
did not find more than three cells per mesangial area in any of
the specimens examined. Therefore, since this was within the
normal range, any expansion of the mesangial volume fraction
was assumed to be due to increased matrix production.
Statistical analysis
All data are expressed as mean standard error of the mean.
Differences between groups for expansion of the mesangial
volume fraction were assessed using a Student's f-test for
independent groups. In addition, differences in fractional me-
sangial volume among all five groups at one year were tested
using an analysis of variance with Bonferroni's method for
comparing multiple groups [30]. Since we reviewed a large
number of glomeruli from each renal cortex (>50) we did not do
an arcsine transformation. Additionally, estimates of the degree
of interstitial fibrosis and GS in the kidneys of the dogs studied
at one year versus those initially removed at the beginning of
the study were assessed by a Mann-Whitney test for nonpara-
metric data. Lastly, we used multiple regression analysis to
compare slopes of the lines that demonstrate the relationship
between changes in urinary protein excretion and mesangial
volume fraction. Statistical significance was designated at a
level of P < 0.05 for all analyses.
A 
164 Gaber et a!: Mesangial volume expansion and antihypertensive treatment
Fig. 2. Globally sclerosed glomerulus demonstrating glomerular tuft shrinkage with mesangial volume increase and capillary obliteration. Note
the surrounding interstitial fibrosis and tubular atrophy (PAS; original magnification x 100).
Results
Light microscopy
Untreated diabetic dogs (Group II) demonstrated a substan-
tial increase in the mean percentage of glomeruli with hilar or
focal GS compared to the control (Group I) animals (Figs. 4 and
5). Sclerosis of the glomerular hilum including the most proxi-
mal portion of the mesangium and the vascular pole of the
glomerular tuft was more frequently seen in the diabetic dogs
compared to control uninephrectomized animals (9.5 0.3%,
Group II vs. 2.5 0.2%, Group I; P < 0.05). The amount of
focal GS among the untreated diabetic group was substantially
higher than the control group (4.6 + 0.3%, Group II vs. 0.2 +
0.1%, Group I; P < 0.05). Moreover, there was a good
correlation between the amount of proteinuria present and
degree of focal GS at one year (r = 0.63, Group I; r = 0.92,
Group II; r = 0.86, Group III; r = 0.81, Group IV; r = 0.72,
Group V).
The effects of various antihypertensive drug treatments on
progression of focal, hilar and global GS are depicted in Figures
4 through 6. While all treated groups manifested a marked
reduction in the amount of focal GS, the extent of the lesion
remained greater when compared to control dogs (Fig. 5).
Furthermore, combination therapy did not provide any greater
benefit on slowing progression of focal or hilar GS over either
agent alone, (Figs. 4 through 6). Lastly, a marked increase in
global GS was noted only among diabetic dogs that received
TA3090 alone. This increase in global GS, however, was not
seen in the combined therapy group (Fig. 6).
Tubulointerstitial disease
The tubulointerstitial changes consisted of atrophic renal
tubules with thickened, wrinkled basement membranes and
simplified epithelium embedded in a fibrotic interstitium that
often contained plasma cells (Fig. 2). These were not prominent
findings, however, among untreated diabetic dogs (0.6 0.3,
controls vs. 0.9 0.1, untreated DM; P = 0.14). The most
extensive tubulointerstitial disease was noted among dogs with
the greatest amounts of global GS. Specifically, dogs treated
with TA 3090 alone had almost twice as much interstitial
fibrosis compared to untreated DM dogs (0.9 0.1, untreated
DM vs. 1.7 0.4, TA 3090 alone; P < 0.04). No significant
differences in interstitial fibrosis were noted between the groups
that received lisinopril and nondiabetic controls (0.6 0.2,
Group III or 0.74 0.2, Group V vs. 0.6 0.3, control).
Mesangial volume fraction
The mean value of the mesangial volume fraction for the
non-diabetic (control) dogs was 0.18 0.01 m2//sm2 following
one year of observation. As expected, induction of diabetes
•r.y :•(I
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Fig. 3. Electronmicroscopy photomicrographs taped together to reconstruct the glomerulus. A grid was superimposed to calculate the mesangial
density (V.,).
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Fig. 4. The amount of axial sclerosis present in each of the five groups
of dogs studied. Group I, nondiabetic control; Group II, diabetic
untreated; Group Ill, diabetic + lisinopril; Group IV, diabetic + TA
3090; Group V, diabetic + lisinopriliTA3090,each in reduced doses.
<0.05 compared to all groups; tP C 0.05 compared to Group II.
resulted in significant expansion of the mesangial volume frac-
tion as the mean V., in Group 11(0.28 0.04 j.tm2/sm2) was
approximately 60% greater than in group I (P < 0.05). Figure 7
is a summary of the changes in the mesangial volume fraction
0
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Fig. 5. The amount offocal glomerulosclerosis present in each of the
five groups of dogs studied. Group I, nondiabetic control; Group II,
diabetic untreated; Group III, diabetic + lisinopril; Group IV, diabetic
+ TA 3090; Group V, diabetic + lisinopril/TA3090, each in reduced
doses. *JP C 0.05 compared to all Groups; tP C 0.05compared to Group
II,
associated with different antihypertensive drug interventions at
similar levels of arterial pressure reduction. The attenuated
increase in mesangial volume fraction observed between lisino-
pril and TA 3O9Gat one year was not statistically different (42±
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Fig. 6, The amount ofglobal glomeruloselerosis present in each of the
five groups of dogs studied. Group I, nondiabetic control; Group 11,
diabetic untreated; Group II!, diabetic + lisinoprit; Group IV, diabetic
+ TA 3090; Group V. diabetic + lisinoprilPFA3O9O, each in reduced
doses. p < 0.05 compared to any of the other groups.
I II Ill IV V
Fig. 7. The effects of different antihypertensive treatments, diabetes
alone and norm a! aging on mesangial volume expansion in unilaterally
nephrectomized diabetic dogs. Each dot represents a single dog. Each
group was compared to each other at the same time point, that is. one
year. Mean standard error of the mean for each group is presented
next to the individual dots for each group. The shaded area represents
the normal mnge for mesangial volume. Group I, nondiabetic control;
Group fl diabetic untreated; Group III, diabetic + lisinopril; Group IV,
diabetic + TA 3090; Group V, diabetic + lisinopriL'TA3090, each in
reduced doses. p C 0.05 compared to any of the other groups.
0.20
0.19
0_la
0.17
0.16
0.15
C 0.14
2 0.13
0.12
' 0.11
0.10
0.09
0.08
> 0.07
.! 0.06
0.05
0.04
0.03
0.02
0.01
0.00
A Proteinuria, mg/kg body wi/day
Fig. 8. The predictive value of attenuating the rise in proteinuria on
increases in fractional inesangial volume in the unilaterally nephrecto-
mized diabetic dog. Group I, nondiabetic control; Group II, diabetic
untreated; Group HI, diabetic + lisinopril; Group IV, diabetic + TA
3090; Group V. diabetic + lisinopril/TA3090, each in reduced doses. 93
<0.002 slope different from Group Ill; 93 C 0.001 slope different from
Group V; 93 < 0.004 slope different from Group I; 93 C 0.05 slope
different from Group IV. Symbols are: (0) Group I; CCX) Group II; (•)
Group II!; (0) Group IV: (•) Group V. Linear regression equations:
Group!, 0.98x + 0.172; Group II, 0.96x + 0.153; Group 111, 0.79x +
0.099; Group IV, 0.88x + 0.192; Group V. 0.78x + 0.15.
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reduced expansion in the fractional mesangial volume was
found in Groups I through III and V (r 0.61, Group I; r =
0.97, Group II; r = 0.79, Group Ill and r = 0.82, Group V). The
weakest correlation was present in Group !V (r = 0.29).
Moreover, a comparison of the slopes between individual
groups demonstrated a significant difference between untreated
diabetic animals and Groups I, I!! and V but not IV, (Fig. 8).
This difference, however, should be viewed in the context of
relatively small numbers of dogs completed in each group as
well as a large scatter among the data sets. Moreover, the
slopes between Groups I, III and V ranged in P values between
<0.08 > 0.06.
Discussion
This study extends our previous findings with three new
observations. First, chronic administration of a converting
enzyme inhibitor or a nondihydropyridine calcium antagonist,
either alone or in combination, attenuates development of focal
GS and expansion of mesangial volume. Second, treatment with
a nondihyropyridine calcium antagonist alone results in a
marked increase in both global GS and a secondary increase in
parenchymal scarring. Moreover, these increases in global GS
appear to be independent of sustained reductions in arterial
pressure or proteinuria. This is evidenced by a lack of global GS
in either of the two groups that received lisinopril as well as the
untreated diabetic group that remained hypertensive. Lastly,
only the groups that received the converting enzyme inhibitor
had a strong correlation between a blunted rise in proteinuria
and attenuated expansion of the mesangial volume fraction.
Previous animal studies with dihydropyridine calcium antag-
onists in either hypertensive or diabetic rats demonstrate an
4%, L vs. 28 9%, TA 3090; P = 0.15). Moreover, the
combination of TA 3090 + lisinopril did not blunt the expansion
of the mesanglal volume fraction to an extent greater than either
agent alone (36 5%, combined vs. 42 4%, L; P = 0.24 or28
9%, TA 3090; P = 0.17). Note that increases were ascribed in
the mesangial volume fraction to be the result of increases in the
matrix and not the cellular component of the mesangium. This
is based on the fact that no increased numbers of cells per
mesangial area were found in our dog glomeruli. Moreover,
additional studies in the literature support this observation (31].
The relationship between associated changes in proteinuria
and mesangial volume fraction is illustrated in Figure 8. A
strong correlation between a blunted rise in proteinuria and a
•
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increased development of both focal and global GS [14, 19—22].
Our data in diabetic dogs extend these findings by demon-
strating that a nondihydropyridine calcium antagonist can also
increase global GS. Moreover, this increase in global GS was
not related to between group differences in either arterial or
intraglomerular pressures or blood glucose control [25]. Inter-
estingly, the augmented development of global OS was attenu-
ated when the calcium antagonist was combined with a convert-
ing enzyme inhibitor. The mechanism of this effect was not
studied; however, it is probably not related to an elevation in
intraglomerular pressure. This is supported by the fact that
untreated diabetic dogs did not manifest an increase in global
GS, yet had similar levels of intraglomerular pressures when
compared to dogs treated with the calcium antagonist alone
[25].
Increases in global OS may also relate to increases in
arteriolar hyalinosis and concomitant expansion of the mesan-
gial volume fraction. Studies in diabetic patients demonstrate
that development of global OS correlates with the amount of
arteriolar hyalinosis present [32]. Our results support the asso-
ciation between increases in arteriolar hyalinosis and expansion
of mesangial volume but not global GS. Moreover, there was a
disproportionate increase in the development of global GS in
the group treated with the nondihydropyridine calcium antago-
nist alone. This increased development of global GS was in
contradistinction to the development of both mesangial volume
expansion and arteriolar hyalinosis which was distinctly
blunted. This suggests a mechanism other than capillary occlu-
sion, secondary to progressive mesangial volume expansion,
may be responsible for the ultimate development of global GS.
One possible explanation for this phenomenon is periodic or
intermittent hypotension that may have occurred during the one
year follow-up period of the study. The frequency of hypoten-
sive episodes, that is, systolic pressure <90 mm Hg, during the
follow-up period was greatest in the dogs that received TA 3090
alone. Prolonged periods of hypotension could have resulted in
some degree of ischemic injury to this group of animals. The use
of continuous arterial pressure monitoring may provide a clue
to the etiology of this problem. Recent animal studies document
the existence of such technology and its usefulness in address-
ing this issue [33].
Previous studies with dihydropyridine calcium antagonists
demonstrated no abatement in the progression of focal GS in
animal models of diabetes [14, 19, 22]. Conversely, studies with
nondihydropyridine calcium antagonists illustrate an attenuated
progression of this process [34, 35]. Our data confirm the
observations with nondihydropyridine calcium antagonists.
Moreover, our studies extend these findings by demonstrating
an attenuated increase in expansion of mesangial volume frac-
tion with a calcium antagonist or converting enzyme inhibitor,
either alone or combined. The mechanism for this slowed
morphologic progression of diabetic nephropathy may relate to
direct effects of these antihypertensive agents on extracellular
matrix proteins. Specifically, both converting enzyme inhibitors
and the nondihydropyridine calcium antagonist, diltiazem, pre-
vent the reduced synthesis of various matrix proteins such as
heparan sulfate, glucoaminoglycan and others in animal models
of diabetes [36, 371. Additionally, converting enzyme inhibitors,
through their effects on angiotensin II, may interact with other
growth factors, such as endothelin, to effect deposition of
various matrix proteins [38]. Thus, these agents may ameliorate
the morphologic progression of diabetic nephropathy separate
from, but perhaps interrelated to, their intrarenal hemodynamic
effects.
The presence of hyperglycemia is known to increase deposi-
tion of extracellular matrix by mesangial cells [39]. Moreover,
morphometric data from the kidneys of diabetic dogs and rats
indicate that restoration of euglycemia can prevent expansion
of the matrix component of the mesangium and, consequently,
retard progression of diabetic glomerulopathy [40, 41]. Studies
in human subjects with diabetes also support these observations
[42—45]. Interestingly, all our dogs had very poor blood glucose
control and yet those whose blood pressures were reduced to
<106 mm Hg did not develop significant increases in mesangial
volume or focal GS. Thus, in contradistinction to previous
reports [23], these data support the concept that blood pressure
reduction plays a very important role in the preservation of
renal function and that both converting enzyme inhibitors and
nondihydropyridine calcium antagonists may have effects on
progression of diabetic nephropathy independent of blood glu-
cose control.
The relationship between increases in proteinuna and expan-
sion of mesangial volume are well documented in both rodent
and canine models of diabetes. Moreover, a recent study by
Steffes et al demonstrates a strong correlation between concom-
itant increases in both the matrix component of the inesangium
and albuminuria among type I diabetic patients [31]. Our data
support these observations. Moreover, we demonstrated that
dogs taking a converting enzyme inhibitor had a persistently
small amount of proteinuria which correlated with both a
blunted expansion of mesangial volume and development of
focal OS.
Tubulointerstitial fibrosis is a common lesion in advanced
diabetic nephropathy and is indicative of irreversible renal
jury [10, 46—49]. Studies involving a rat model of immune
injv demonstrate that tubulointerstitial disease precedes de-
velopnnt of GS [50, 51]. A possible etiologic factor in our
study relatc.. to the alloxan used to make the dogs
diabetic [24]. However, this would not account for the clear
predominance of tubulointerstitial fibrosis observed only in the
group that received single agent treatment with TA 3090.
Interestingly, this was also the only group to manifest a
significant increase in global OS. Unfortunately, we did not do
serial biopsies and thus cannot comment on the time course or
association of this process to OS.
In summary, our results indicate that the morphologic events
associated with diabetic nephropathy are slowed by treatment
with either a converting enzyme inhibitor or heart-rate-lowering
calcium antagonist, administered either alone or together.
When used alone, however, the calcium antagonist reduced
mesangial volume expansion but increased the amount of global
GS and tubulointerstitial fibrosis. The co-administration of each
agent, however, prevented this occurrence. The mechanism
underlying the genesis of global OS in this model is unclear but
may relate to periodic or persistent hypotension and warrants
further study.
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